Ervimmune

Developer of immunotherapies for the treatment of cancer

placeLyon, Auvergne Rhone Alpes, France calendar_todayFounded 2019 language ervimmune.com

Innovation

5 patent families — focus: Chemistry & metallurgy, Physics & computing, Human necessities; filing pace active. Cited 24 times.

YearFilings
20243
20255

Social engagement

Social engagement: 2.7K social following, 1 post in the last 12 months — below the industry typical range.

Investor mix

4 investors on record; lead investors include Seventure Partners, Bpifrance.

Investor typeCountShare
Venture capital250%
Accelerator & incubator125%
Bank & private debt125%

Hiring activity

Hires occasionally

1 role tracked across 1 of the last 12 months

20 May 2026 · Bioinformatics Engineers, Data Scientists – Immuno-Oncology

Based on job postings tracked across public sources.

Coming soon